Yingmin Ma

Suggest Changes
  • Citations Per Year
Learn More
BACKGROUND The effect of combined administration of the multi-targeted receptor tyrosine kinase (RTK) inhibitor (Sorafenib) and chemotherapy (Pemetrexed) is still unknown. The cytotoxicity, the(More)
  • 1